About Me

David Sans, FAARM, Ph.D., M.B.A., is a Chemical Engineer with a PhD in Chemometrics and Artificial Intelligence from Dr. Stoessel's ETH Zurich laboratory and a Mount Sinai Board Certification in Cell Therapies. David holds FINRA Series 7, 63, 15, and 55 licenses in Healthcare Investment Banking.

David has over 12 years of experience in healthcare investment banking, where he has provided a full range of investment banking advisory services, including mergers and acquisitions, project finance, capital raising, and exceptional situations. David's customers have completed over 100 Healthcare Investment Banking transactions for financial institutions, healthcare institutional investors, and strategic partners since 2008. David founded the AI Pathology platform at Mount Sinai Hospital in New York in 2012 and sold it to Philips in 2021, among other things. Annovis Bio, which raised $600 million in value from a $10 million IPO in December 2020, is one of David's IPOs. David worked at ImClone Systems as the Vice President of Finance and Investment Strategy, reporting to the CEO and the Board of Directors, and at ThinkEquity as the Managing Director of Healthcare Banking. David began his career as a Sr. Medical Scientist at Novartis during the introduction of Glivec® (Imatinib) in Switzerland, then moved on to Pfizer as the Director of Market Analytics for Rebif® (interferon beta-1a for MS) and Macugen.


David Sans Portfolio